Press Room

DDL 2017

Start
Wednesday, December 06, 2017 - 00:00
End
Wednesday, December 06, 2017 - 00:00
Location: Scotland, UK
Booth Number: 420
drug product manufacturing | Hovione

Hovione will be attending DDL 2017 in Edinburgh, Scotland. 

Hovione is present with a booth where our experts and the business team can explain about our services and technologies in the inhalation area. Also, 4 posters will be presented, covering the areas of Particle Engineering, Formulation Development and Advanced Analytical Characterization. Hovione Technology also attended the conference presenting the company portfolio of DPI devices.

 

HOVIONE POSTERS

Dissolution of Orally Inhaled Drugs using DissolvIt®Influence of a Newly Designed Pre-Separator for Particle Collection

Beatriz NoriegaEunice Costa, Filipa Maia

Spray Dried Composite Particles: Formulation and Process Parameters, Effect of two API Concentrations and Stability Assessment

Maria Palha, Raquel Barros, Cláudia Moura, Sofia Silva, Sara Cardoso, Eunice Costa, Márcio Temtem

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us.

Marcel Hogerheide will be pleased to meet you.

Marcel Hogerheide  | Hovione

Marcel Hogerheide

Head of Account Management & Business Development

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026